If you have been reading about Cardarine and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-12-12. Numbers and descriptions here follow the published literature rather than marketing material.
Laboratory detection of cardarine typically involves sample preparation followed by chromatographic separation and mass spectrometric identification. Urine is the most common matrix for anti-doping tests, though blood and hair have also been explored. Methods can target the parent compound or its metabolites, depending on the expected window of detection. Reference standards are required for accurate quantification. Matrix effects and dilution can influence results, so laboratories use internal standards and validation protocols. The exact detection window varies with dose, route, and individual metabolism.
A common misconception is that cardarine has been proven safe for human use. In reality, human clinical data are limited, and long-term animal studies have raised concerns about cancer. Another misconception is that it is a supplement or vitamin-like compound. It is a synthetic research chemical with no approved medical indication. Scientific discussion often focuses on its mechanism and detection rather than therapeutic use. Regulatory and anti-doping literature treats it primarily as a prohibited substance.
Cardarine is explicitly prohibited by the World Anti-Doping Agency under the class of PPARδ agonists. Its presence in urine or blood samples can be detected using mass spectrometry-based methods, often liquid chromatography-tandem mass spectrometry. Athletes who test positive may face sanctions, including bans from competition. The compound is also regulated as a prescription-only or unapproved drug in many countries. Enforcement varies by jurisdiction, and some regions treat it as a controlled substance. Online sales may occur despite these restrictions, creating quality and legal risks.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA as a PPARδ agonist. |
| Typical detection matrix | Urine | Most common sample for anti-doping analysis. |
| Common analytical method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry. |
| Common synonyms | GW501516, GSK-516, endurobol | Names found in research and fitness contexts. |
| Typical detection window | Variable | Depends on dose, route, and individual metabolism. |
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
== Metabolism == cADPR and ADPR are synthesized from NAD+ by the bifunctional ectoenzymes of the CD38 family (also includes the GPI-anchored CD157 and the specific, monofunctional ADP ribosyl cyclase of the mollusc Aplysia). The same enzymes are also capable of hydrolyzing cADPR to ADPR. Catalysis proceeds via a covalently bound intermediate. The hydrolysis reaction is inhibited by ATP, and cADPR may accumulate. Synthesis and degradation of cADPR by enzymes of the CD38 family involve, respectively, the formation and the hydrolysis of the N1-glycosidic bond. In 2009, the first enzyme able to hydrolyze the phosphoanhydride linkage of cADPR, i.e. the one between the two phosphate groups, was reported. SARM1 and other TIR domain-containing proteins also catalyze the formation of cADPR from NAD+.
An ingredient in diesel exhaust fluid (DEF), which is 32.5% urea and 67.5% de-ionized water. DEF is sprayed into the exhaust stream of diesel vehicles to break down dangerous NOx emissions into harmless nitrogen and water. A component of animal feed, providing a relatively cheap source of non-protein nitrogen to promote growth. A non-corroding alternative to rock salt for road de-icing. It is often the main ingredient of pet friendly salt substitutes although it is less effective than traditional rock salt or calcium chloride. A main ingredient in hair removers such as Nair and Veet. A browning agent in factory-produced pretzels. An ingredient in some skin cream, moisturizers, hair conditioners, and shampoos. A cloud seeding agent, along with other salts. A flame-proofing agent, commonly used in dry chemical fire extinguisher charges such as the urea-potassium bicarbonate mixture. Along with diammonium phosphate, as a yeast nutrient, for fermentation of sugars into ethanol. A nutrient used by plankton in ocean nourishment experiments for climate engineering purposes. As an additive to extend the working temperature and open time of hide glue. As a solubility-enhancing and moisture-retaining additive to dye baths for textile dyeing or printing. As an optical parametric oscillator in nonlinear optics. To help prepare an alpine skiing course by hardening the snow into a icier surface to maintain the integrity of the course.
Thus, truly comprehensive or 'deep' proteome analyses must assess proteoforms. There are two general approaches to proteome analysis - bottom up (BUP or shotgun) and top down (TDP). The former, a peptide-centric or proteogenomic approach, infers (often with quite limited data) the identities of canonical protein sequences by correlation with existing databases, mostly derived from genome sequencing projects. In contrast, TDP can, in theory, yield comprehensive proteome analyses at the level of proteoforms provided the methods used effectively address the full breadth of species in a proteome.
Sources: en.wikipedia.org
=== Sexual role reversal === It is common among Lepidoptera for females to use pheromones to attract males for mating. In T. ni, both males and females produce pheromones capable of attracting the opposite sex. This has been cited as an example of sexual role reversal.
=== Funding and revenue === In 2023, Breakthrough T1D raised $224 million; of this, 78% went toward programs including research funding, 15% was spent on fundraising, and 7% was spent on administrative costs. Cumulatively, Breakthrough T1D was funding approximately $568 million in T1D research projects worldwide in 2018.
The authors hypothesized that the higher levels of CD8+ T cell infiltration was due to anti-CTLA-4 inhibited the conversion of CD4 T cells to T regulator cells and further reduced T regulatory suppression with anti-PD-1. This combination promoted a more robust inflammatory response to the tumor that reduced the size of the cancer. Most recently, the FDA has approved a combination therapy with both anti-CTLA4 (ipilimumab) and anti-PD1 (nivolumab) in October 2015. The molecular factors and receptors necessary making a tumor receptive to anti-PD1 treatment remains unknown. PD-L1 expression on the surface on cancer cells plays a significant role. PD-L1 positive tumors were twice as likely to respond to combination treatment. However patients with PD-L1 negative tumors also have limited response to anti-PD1, demonstrating that PD-L1 expression is not an absolute determinant of the effectiveness of therapy. Higher mutational burden in the tumor is correlated with a greater effect of the anti-PD-1 treatment. In clinical trials, patients who benefited from anti-PD1 treatment had cancers, such as melanoma, bladder cancer, and gastric cancer, that had a median higher average number of mutations than the patients who did not respond to the therapy. However, the correlation between higher tumor burden and the clinical effectiveness of PD-1 immune blockade is still uncertain. The 2018 Nobel Prize for Medicine was awarded to James P Allison and Tasuku Honjo "for their discovery of cancer therapy by inhibition of negative immune regulation".
Lula met with Pope Francis on the Vatican City on 12 June after his diner with Italian President Sergio Mattarella, during the meeting at Paul VI's room, they reportedly discussed "peace and reconciliation, environmental preservation, respect for indigenous populations and the fight against hunger, inequality and poverty in the world", according to Brazilian and Holy See officials, although there was no explicit mention to the current Russo-Ukrainian war, Lula reportedly wanted to talk about a possible peaceful solution of the conflict with the Pope, but neither side mentioned any talks about that particular subject. Lula gave the Pope an engraving of the Holy Family made by Pernambuco artist J. F. Borges, while Rosângela brought the Pontiff an image of Our Lady of Nazaré, patroness of the Amazon, while the Pope gave Lula and Janja a bronze art with the phrase "Peace is a fragile flower", he also presented the couple with a copy of his Message of Peace for 2023, the document on Human Fraternity and the book with the prayer he did in a deserted St. Peter's Square, on 27 March 2020, praying for the end of the COVID-19 pandemic, Lula and Janja also invited the priest to travel to Pará to participate in the "Círio" in October of that year, but acceptance must depend on the state of health of the Pontiff, who was discharged from his most recent hospitalization, the second in two months, on Friday, after the meeting with the Pope, Lula had met with Dom Edgar Peña Parra, responsible for General Affairs at the Vatican Secretariat of State.
Sources: en.wikipedia.org
Chell can pick up weighted storage cubes and use them to climb or hold down large buttons that activate doors and other mechanisms. Particle fields known as "Emancipation Grills" appear at the ends of test chambers and in other locations; passing through them removes active portals and destroys objects carried through them. The fields also prevent the player from firing portals through them. Chell is equipped with mechanical heel springs that reduce the effects of falling, but she can still be killed by hazards including automated turrets, energy projectiles, toxic liquid, falling objects, and crushing mechanisms. The game does not display a conventional health bar; instead, Chell dies after sustaining sufficient damage within a short period. Certain hazards, including some energy projectiles and crushing mechanisms, can kill her immediately. The test chambers can be completed through different solutions, with players able to use the portal mechanics and physics in different ways to overcome the puzzles. After completing the main game, two additional modes become available: Challenge Chambers and Advanced Chambers. Challenge Chambers revisit existing test chambers with additional objectives based on completing them with the fewest portals, the fewest footsteps, or the shortest time. Advanced Chambers modify existing chambers by adding obstacles and other hazards.
Selodenoson ((2S,3S,4R)-5-(6-(cyclopentylamino)-9Hpurin-9-yl)-N-ethyl-3,4-dihydroxytetrahydrofuran-2-carboxamide) Capadenoson (BAY68-4986) Benzyloxy-cyclopentyladenosine (BnOCPA) is an A1R selective agonist.
His first tournament brought immediate reward. Colombia went through the group stage of the 1987 Copa América unbeaten, lost 2–1 to Chile in the semi-final, then beat the hosts Argentina 2–1 at the Monumental on 11 July through Gabriel Jaime Gómez and John Jairo Galeano, Claudio Caniggia replying late before 15,000 spectators. Arnoldo Iguarán finished as the tournament's leading scorer with four goals. The revival coincided with an influx of narcotics money into the domestic game. Atlético Nacional, funded through the Medellín Cartel and its leader Pablo Escobar, retained Colombian internationals who would otherwise have moved abroad and recruited foreign players the league could not previously afford; Maturana, who managed the club from 1987 to 1990, later acknowledged that "the introduction of drug money into soccer allowed us to bring in great foreign players. It also kept our best players from leaving. Our level of play took off." On 31 May 1989 Nacional, fielding Higuita, Andrés Escobar, Leonel Álvarez and Albeiro Usuriaga, beat Olimpia 5–4 on penalties at El Campín to become the first Colombian club to win the Copa Libertadores, supplying Maturana with a ready-made international spine. Colombia were eliminated in the group stage of the 1989 Copa América in Brazil, a 1–0 loss to Paraguay proving decisive despite a goalless draw with the eventual champions. The World Cup qualifiers opened a fortnight later.
Q-cytochrome c oxidoreductase is also known as cytochrome c reductase, cytochrome bc1 complex, or simply complex III. In mammals, this enzyme is a dimer, with each subunit complex containing 11 protein subunits, an [2Fe-2S] iron–sulfur cluster and three cytochromes: one cytochrome c1 and two b cytochromes. A cytochrome is a kind of electron-transferring protein that contains at least one heme group. The iron atoms inside complex III's heme groups alternate between a reduced ferrous (+2) and oxidized ferric (+3) state as the electrons are transferred through the protein. The reaction catalyzed by complex III is the oxidation of one molecule of ubiquinol and the reduction of two molecules of cytochrome c, a heme protein loosely associated with the mitochondrion. Unlike coenzyme Q, which carries two electrons, cytochrome c carries only one electron.
=== EC 1.12.1 With NAD+ or NADP+ as acceptor === EC 1.12.1.1: Now EC 1.12.7.2, ferredoxin hydrogenase EC 1.12.1.2: hydrogen dehydrogenase EC 1.12.1.3: hydrogen dehydrogenase (NADP+) EC 1.12.1.4: hydrogenase (NAD+, ferredoxin) EC 1.12.1.5: hydrogen dehydrogenase [NAD(P)+]
Sources: en.wikipedia.org
Yes, WADA prohibits cardarine as a PPARδ agonist. It appears on the prohibited list and can be detected in urine or blood. Athletes using it risk sanctions.
Detection usually uses liquid chromatography-tandem mass spectrometry after sample cleanup. Laboratories look for the parent compound or metabolites. The method requires validated reference standards and controls.
Legality varies by country. In many places it is an unapproved drug and cannot be legally sold for human consumption. Purchasing from online vendors carries legal and quality risks.
Cardarine is a common name for the investigational compound GW501516. It acts as a PPARδ agonist and is not approved for human use. It is prohibited in sport.